Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS9432 in Candidemia and/or Invasive Candidiasis
NCT06194201Phase 2Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Apr 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of HRS9432 in candidemia, invasive candidiasis, sponsored by Fujian Shengdi Pharmaceuticals. Started Apr 2024; status: completed.
02
Drugs
HRS9432
03
Conditions
candidemiainvasive candidiasis
Beyond the preview
Go deeper on NCT06194201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06194201.